Title: Metabolic Outcomes in Non-Alcoholic and Alcoholic Steatotic Liver Disease among
Korean and American Adults
Version: 0 Date: 05 Dec 2024
Reviewer's report:
In this manuscript entitled “Metabolic Outcomes in Non-Alcoholic and Alcoholic Steatotic
Liver Disease among Korean and American Adults”, the authors examined the association
between steatotic liver disease and metabolic disorders. While this is an interesting study, there
are some concerns which should be clarified.
Major comments
1. The introduction explaining NAFLD can be deleted because this study did not evaluate
NAFLD and the readers of the manuscript are hepatologists who understand the renaming. In
addition, NAFLD in page 11, line 277 can be changed to MASLD. Furthermore, the authors
should change the term “fatty liver” to “steatotic liver” throughout the paper.
2. In the introduction, the authors should explain the epidemiology of MASLD in general
population. (PMID: 38398471).
3. Cardiometabolic criteria is required for the diagnosis of MASLD and MetALD. The authors
should precisely explain in the method section.
4. The rationale for choosing different HSI thresholds for Korean and American cohorts (36 and
41, respectively) needs further justification. Especially, previous studies suggest lower cutoff
values for HSI in Asian cohort (PMID: 38895100, PMID: 33467114).
5. Sex difference of body composition may also influence MASLD and cardiometabolic diseases
The authors should make a discussion in this point (PMID: 37143429).
6. While the study emphasizes the need for integrated management of liver health and metabolic
risk factors, specific actionable recommendations for clinicians or policymakers are lacking.
Minor comments
1. “HIS” in line 119 should be “HSI”. The authors should check throughout the paper.
2. “MASDL” in line 264 should be “MASLD”.
Title: Metabolic Outcomes in Non-Alcoholic and Alcoholic Steatotic Liver Disease among
Korean and American Adults
Version: 0 Date: 05 Dec 2024
Reviewer's report:
In this manuscript entitled “Metabolic Outcomes in Non-Alcoholic and Alcoholic Steatotic
Liver Disease among Korean and American Adults”, the authors examined the association
between steatotic liver disease and metabolic disorders. While this is an interesting study, there
are some concerns which should be clarified.
Major comments
1. The introduction explaining NAFLD can be deleted because this study did not evaluate
NAFLD and the readers of the manuscript are hepatologists who understand the renaming. In
addition, NAFLD in page 11, line 277 can be changed to MASLD. Furthermore, the authors
should change the term “fatty liver” to “steatotic liver” throughout the paper.
2. In the introduction, the authors should explain the epidemiology of MASLD in general
population. (PMID: 38398471).
3. Cardiometabolic criteria is required for the diagnosis of MASLD and MetALD. The authors
should precisely explain in the method section.
4. The rationale for choosing different HSI thresholds for Korean and American cohorts (36 and
41, respectively) needs further justification. Especially, previous studies suggest lower cutoff
values for HSI in Asian cohort (PMID: 38895100, PMID: 33467114).
5. Sex difference of body composition may also influence MASLD and cardiometabolic diseases
The authors should make a discussion in this point (PMID: 37143429).
6. While the study emphasizes the need for integrated management of liver health and metabolic
risk factors, specific actionable recommendations for clinicians or policymakers are lacking.
Minor comments
1. “HIS” in line 119 should be “HSI”. The authors should check throughout the paper.
2. “MASDL” in line 264 should be “MASLD”.
Please review this paper.
user
Title: Metabolic Outcomes in Non-Alcoholic and Alcoholic Steatotic Liver Disease among
Korean and American Adults
Version: 0 Date: 05 Dec 2024
Reviewer's report:
In this manuscript entitled “Metabolic Outcomes in Non-Alcoholic and Alcoholic Steatotic
Liver Disease among Korean and American Adults”, the authors examined the association
between steatotic liver disease and metabolic disorders. While this is an interesting study, there
are some concerns which should be clarified.
Major comments
1. The introduction explaining NAFLD can be deleted because this study did not evaluate
NAFLD and the readers of the manuscript are hepatologists who understand the renaming. In
addition, NAFLD in page 11, line 277 can be changed to MASLD. Furthermore, the authors
should change the term “fatty liver” to “steatotic liver” throughout the paper.
2. In the introduction, the authors should explain the epidemiology of MASLD in general
population. (PMID: 38398471).
3. Cardiometabolic criteria is required for the diagnosis of MASLD and MetALD. The authors
should precisely explain in the method section.
4. The rationale for choosing different HSI thresholds for Korean and American cohorts (36 and
41, respectively) needs further justification. Especially, previous studies suggest lower cutoff
values for HSI in Asian cohort (PMID: 38895100, PMID: 33467114).
5. Sex difference of body composition may also influence MASLD and cardiometabolic diseases
The authors should make a discussion in this point (PMID: 37143429).
6. While the study emphasizes the need for integrated management of liver health and metabolic
risk factors, specific actionable recommendations for clinicians or policymakers are lacking.
Minor comments
1. “HIS” in line 119 should be “HSI”. The authors should check throughout the paper.
2. “MASDL” in line 264 should be “MASLD”.
assistant